New Enterprise Associates 13 Lp - Jan 29, 2024 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
10%+ Owner
Signature
/s/ Stephanie Brecher, attorney-in-fact
Stock symbol
SGMT
Transactions as of
Jan 29, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 04:55 PM
Previous filing
Jul 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMT Series A Common Stock Other $0 -850K -22.08% $0.00 3M Jan 29, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

New Enterprise Associates 13 Lp is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 New Enterprise Associates 13, L.P. ("NEA 13") made a pro rata distribution of 850,000 shares of Series A Common Stock of the Issuer to its general partner and limited partners for no consideration on January 29, 2024.
F2 The securities are directly held by NEA 13 and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13, and the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors"), together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are Forest Baskett, Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Indirect Reporting Persons have no pecuniary interest.